trending Market Intelligence /marketintelligence/en/news-insights/trending/4QC3QhkVM1HSI5Sq9-a_GA2 content esgSubNav
In This List

Kitov gets FDA approval to brand osteoarthritis, hypertension drug as Consensi

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Kitov gets FDA approval to brand osteoarthritis, hypertension drug as Consensi

The U.S. Food and Drug Administration allowed Kitov Pharmaceuticals Holdings Ltd. to use the brand name Consensi for marketing its drug KIT-302.

The permission is subject to receipt of marketing approval from the regulator.

Consensi is a combination of two FDA-approved drugs — Pfizer Inc.'s Celebrex and Norvasc. It is intended to simultaneously treat pain caused by osteoarthritis, as well as hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain.

The expected completion date for FDA's review of the new drug application for Consensi is May 31, 2018.